| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$24 |
Investor Webinar Presentation - Q2 FY26
|
29 Jan 2026 9:13AM |
$0.079 |
$0.051 |
fallen by
35.44%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI received purchase orders for five devices in Q2 FY26.
- A $4.0 million milestone investment was triggered and is pending final receipt.
- Regulatory engagement for HiRise™ in China is advancing with WEGO Orthopaedics.
- FDA 510(k) application submitted for BMD module, clearance targeted for mid-CY26.
- HiRise™ project for robotic-aided surgical systems is progressing.
- Cash balance reported at A$8.03 million including pending WEGO payment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| CurveBeam AI Limited (CVB) ORDINARY FULLY PAID |
Health Care |
$24 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Jan 2026 9:12AM |
$0.079 |
$0.051 |
fallen by
35.44%
|
|
CVB - Price-sensitive ASX Announcement
Full Release
Key Points
- CurveBeam AI received five purchase orders, including four HiRise™ and one LineUp device.
- The company progressed its agreement with Shandong WEGO Orthopaedics, triggering a $4.0 million investment.
- FDA 510(k) application submitted for the BMD module, with clearance expected by mid-2026.
- Net cash used in operations was A$2.15 million, depicting improvement from the previous quarter.
- Equity financing added A$4.03 million, with R&D tax rebate received.
- Enhanced validation efforts for HiRise™ system compatibility with robotic surgery systems.
- Significant promotional activities for HiRise™ initiated in China under NMPA registration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arafura Rare Earths Ltd (ARU) ORDINARY FULLY PAID |
Materials |
$1,264 |
Quarterly Activities and Appendix 5B
|
29 Jan 2026 9:12AM |
$0.265 |
$0.270 |
risen by
1.89%
|
|
ARU - Price-sensitive ASX Announcement
Full Release
Key Points
- Arafura Rare Earths Ltd progressed its Greenhouse Gas Emissions Reduction Pathway, aiming for net zero by 2050.
- The company is exploring the use of concentrated solar thermal for steam generation to reduce emissions.
- Local stakeholder engagement continues, including meetings with Traditional Owners and local service providers.
- Meetings with government officials emphasize support for the Nolans Project.
- Arafura has secured significant equity funding, including a US$300 million non-binding interest from US EXIM.
- Cash position improved significantly to A$571 million by the end of 2025.
- The company is advancing its Local and Indigenous Workforce Development Program.
- Environmental management includes the refinement of systems to align with regulatory and operational requirements.
- Exploration activities at Nolans Bore focused on mining-related studies.
- The NdPr market experienced price increases due to global trade tensions and supply chain vulnerabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$85 |
ALA's IND FOR ALA-101 ACCEPTED BY THE U.S.FDA
|
29 Jan 2026 9:11AM |
$0.088 |
$0.070 |
fallen by
20.45%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- U.S. FDA accepted IND application for ALA-101.
- Enables first-in-human clinical trials for CD19-positive NHL and leukemia.
- Regulatory validation de-risking Arovella's clinical development plan.
- ALA-101 is engineered with CAR19-iNKT cells for scalable 'off-the-shelf' dosing.
- The IND acceptance provides a framework for future CAR-iNKT cell programs.
- Will conduct phase 1 trial in Australia via CTN scheme.
- Anticipates expanding development for other solid tumor products.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Resources Australia Ltd (AR1) ORDINARY FULLY PAID |
Materials |
$170 |
Site Visit Presentation
|
29 Jan 2026 9:11AM |
$0.120 |
$0.080 |
fallen by
33.33%
|
|
| Viking Mines Limited (VKA) ORDINARY FULLY PAID |
Materials |
$33 |
VKA TO COMMENCE HIGH-RESOLUTION GEOPHYSICS AT LINKA PROJECT
|
29 Jan 2026 9:10AM |
$0.012 |
$0.014 |
risen by
12.50%
|
|
| Peak Processing Limited (PKP) ORDINARY FULLY PAID |
Health Care |
$19 |
Trading Halt
|
29 Jan 2026 9:10AM |
$0.019 |
$0.016 |
fallen by
15.79%
|
|
PKP - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading halt requested by Peak Processing Limited (PKP).
- Trading halt related to a proposed capital raise.
- Halt will last until 2 February 2026 or announcement release.
- Necessary for managing continuous disclosure obligations.
- Expected announcement before normal trading on 2 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rhythm Biosciences Limited (RHY) ORDINARY FULLY PAID |
Health Care |
$61 |
Rhythm Biosciences secures strategic alliance with AGRF
|
29 Jan 2026 9:09AM |
$0.150 |
$0.185 |
risen by
23.33%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$4 |
Appendix 5B - Quarterly Cash Flow Report
|
29 Jan 2026 9:09AM |
$0.030 |
$0.017 |
fallen by
43.33%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Cash Flow Report
- Cash flows for the quarter ending 31 December 2025
- Steps for raising further cash are planned
- Board confident in successful fundraising
- Compliance with ASX Listing Rules and Australian Accounting Standards
- Report authorised by the Board of Directors
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Venus Metals Corporation Limited (VMC) ORDINARY FULLY PAID |
Materials |
$41 |
Strategic Review and Appointment of Financial Advisor
|
29 Jan 2026 9:08AM |
$0.215 |
$0.210 |
fallen by
2.33%
|
|
| Diablo Resources Limited (DBO) ORDINARY FULLY PAID |
Materials |
$4 |
Quarterly Activities Report
|
29 Jan 2026 9:08AM |
$0.030 |
$0.017 |
fallen by
43.33%
|
|
DBO - Price-sensitive ASX Announcement
Full Release
Key Points
- Star Range Silver-Antimony Project saw 186 claims staked covering 14.5km².
- Initial sampling returned high-grade silver and antimony results.
- Drone aeromagnetic survey completed with results expected in Q1 2026.
- Phoenix Copper Project's maiden drill program revealed promising copper results.
- Matthew Blumberg joined as a Non-Executive Director.
- Diablo held $943,000 in cash at quarter-end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Woolworths Group Limited (WOW) ORDINARY FULLY PAID |
Consumer Staple |
$44,283 |
Woolworths Group Board update
|
29 Jan 2026 9:08AM |
$30.410 |
$36.250 |
risen by
19.20%
|
|
| New Age Exploration Limited (NAE) ORDINARY FULLY PAID |
Energy |
$8 |
Drill Program Completed at Wagyu Gold Pilbara
|
29 Jan 2026 9:07AM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
NAE - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of 40 RC drill holes totaling 4,034 meters at the Wagyu Gold Project.
- Targeted high-grade gold extensions associated with Hemi-style intrusives.
- Drill samples sent to Intertek Laboratories in Perth with results expected in February and March 2026.
- The Wagyu Gold Project is located near the 11.2Moz Hemi Gold Deposit.
- Visual geological observations suggest the presence of intrusive lithologies and alterations.
- NAE Executive Director highlighted the significance of the program in understanding the intrusive system.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cokal Limited (CKA) ORDINARY FULLY PAID |
Materials |
$73 |
Mining Progress Following Infrastructure Completion
|
29 Jan 2026 9:07AM |
$0.077 |
$0.068 |
fallen by
11.69%
|
|
| Retail Food Group Limited (RFG) ORDINARY FULLY PAID |
Consumer Discretionary |
$64 |
Final Director's Interest Notice
|
29 Jan 2026 9:06AM |
$1.490 |
$1.020 |
fallen by
31.54%
|
|
| Retail Food Group Limited (RFG) ORDINARY FULLY PAID |
Consumer Discretionary |
$64 |
Resignation of Director
|
29 Jan 2026 9:06AM |
$1.490 |
$1.020 |
fallen by
31.54%
|
|
| INOVIQ Ltd (IIQ) ORDINARY FULLY PAID |
Health Care |
$49 |
Quarterly Business Update and Appendix 4C - December 2025
|
29 Jan 2026 9:05AM |
$0.365 |
$0.345 |
fallen by
5.48%
|
|
IIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- INOVIQ is advancing its exosome ovarian cancer screening test, EXO-OC™, with demonstrated high sensitivity and specificity.
- Positive in vivo proof-of-concept results were achieved for CAR-exosome therapeutics targeting triple-negative breast cancer.
- The company completed a $10.2 million capital raise to accelerate development programs.
- Financial results show INOVIQ ending the quarter with $13.8 million in cash.
- Strategic leadership changes include the appointment of Dr. Rebecca Lim as Chief Scientific Officer.
- INOVIQ aims to advance their EXO-OC test to Laboratory Developed Test-ready status by the end of 2026.
- The company is focused on partnerships to enhance product development and commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Felix Gold Limited (FXG) ORDINARY FULLY PAID |
Materials |
$143 |
Drilling Confirms Broad Zones of Gold at Treasure Creek
|
29 Jan 2026 9:05AM |
$0.400 |
$0.290 |
fallen by
27.50%
|
|
FXG - Price-sensitive ASX Announcement
Full Release
Key Points
- Felix Gold Limited confirmed broad zones of gold mineralization at Treasure Creek.
- Significant gold grades include 47 meters at 2.45 grams per tonne.
- Proximity to Fort Knox mine, a Tier 1 operation by Kinross Gold.
- Felix Gold is the largest landholder in Fairbanks Gold Mining District with 831,000 ounces of JORC resources.
- Focus on antimony as a critical mineral for U.S. defense and energy.
- Plans for a fully integrated mine-to-metal operation in the U.S.
- Potential for third-party processing agreements.
- Ongoing exploration and expansion of mineral resources.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fortuna Metals Ltd (FUN) ORDINARY FULLY PAID |
Materials |
$22 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jan 2026 9:05AM |
$0.115 |
$0.077 |
fallen by
33.04%
|
|
FUN - Price-sensitive ASX Announcement
Full Release
Key Points
- Material acquisition of rutile and graphite projects in Malawi.
- Significant rutile discovery confirmed by high-grade drill results.
- Completion of $3.5 million placement to advance exploration projects.
- Net cash from operating activities was negative at $310,000 for the quarter.
- Cash and cash equivalents at the end of the quarter were $6.99 million.
- Aggregate payments to related parties during the quarter were $42,448.
- Exploration and evaluation expenditure was $447,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$125 |
Trading Halt
|
29 Jan 2026 9:03AM |
$0.045 |
$0.035 |
fallen by
22.22%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited requested a trading halt.
- The trading halt is related to the interim analysis of the XanaMIA Phase 2b/3 Alzheimer's trial.
- Trading will resume by 2 February 2026 or upon the company's announcement.
- Actinogen Medical is developing Xanamem for Alzheimer's and other neurological conditions.
- The company is awaiting outcomes from clinical trials and interim analyses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evolution Mining Limited (EVN) ORDINARY FULLY PAID |
Materials |
$25,302 |
FY26 Half Year Results Conference Call Notification
|
29 Jan 2026 9:03AM |
$15.350 |
$12.460 |
fallen by
18.83%
|
|
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$201 |
Quarterly Cashflow Report
|
29 Jan 2026 9:02AM |
$1.260 |
$0.840 |
fallen by
33.33%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Barton Gold Holdings Limited released their quarterly cash flow report for the period ending 31 December 2025.
- The report shows a net cash outflow from operating activities of $4,538,000 for the current quarter.
- Investing activities resulted in a net cash outflow of $19,000.
- Significant cash inflows from financing activities totaled $15,660,000, primarily from the issuance of equity securities.
- Cash and cash equivalents at the end of the period were $17,186,000.
- No dividends were paid during the quarter.
- Payments to related parties totaled $203,000, covering director fees and related expenses.
- The company has a $4,425,000 rehabilitation performance bond guarantee facility with Macquarie Bank and a $25,000 office lease guarantee facility provided by Commonwealth Bank.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Prairie Lithium Limited (PL9) ORDINARY FULLY PAID |
Materials |
$33 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Jan 2026 9:01AM |
$0.008 |
$0.006 |
fallen by
25%
|
|
PL9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Secured a 10-year binding export agreement with Hydro Lithium.
- Finalized a non-binding offtake agreement with Stardust Power.
- Completed groundwork and received grid electricity approval for Pad #1.
- Raised $1.45 million through an At-the-Market Subscription Agreement.
- Aiming to establish Canada's first commercial-scale lithium brine production.
- Strong financial position with funding available for seven quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| US1 Critical Minerals Limited (USC) ORDINARY FULLY PAID |
Materials |
$15 |
Appendix 3G
|
29 Jan 2026 9:01AM |
$0.016 |
$0.016 |
fallen by
0%
|
|
| Barton Gold Holdings Limited (BGD) ORDINARY FULLY PAID |
Materials |
$201 |
Quarterly Activities Report
|
29 Jan 2026 8:58AM |
$1.260 |
$0.840 |
fallen by
33.33%
|
|
BGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed a $660,000 Share Purchase Plan at a premium to BGD market price.
- Projected completion of a Definitive Feasibility Study by June 2026.
- Tunkillia Gold Project aims to produce 365koz gold and 923koz silver.
- Challenger Gold Project targets 'Stage 1' operations by end of 2026.
- Tolmer diamond drilling confirms local structural model.
- Addition to ASX All Ordinaries Index.
- Planning follow-up drilling in the 'western silver zone'.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
